Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Exicon Co., Ltd. Capital/Financing Update 2016

Jul 4, 2016

16401_rns_2016-07-04_463b2036-6fc1-41e3-b1c4-d4b0eaa0f8e3.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

EXIQON Seek Find Verify

Announcement

To Nasdaq Copenhagen

Exiqon A/S Skelstedet 16 2950 Vedbæk Denmark

Phone: +45 4566 0888 Fax: +45 4566 1888 [email protected] www.exiqon.com CVR/Tax Id: 18 98 44 31

4 July 2016

ISIN DK 0030368204 - EXIQON A/S DKK 40,000,000 SENIOR SECURED NOTES

Exiqon A/S, listed on Nasdaq Copenhagen ("EXQ"), today has provided Notice of a Change of Control Event to Noteholders following completion of the takeover offer by QIAGEN N.V. in accordance with the attached.

Additional information

Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101) Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)

About Exiqon

At Exiqon, we advance the research of when and where genes are expressed. We empower scientists across the world with best-in-class products and user-friendly business solutions designed to transform workflows in our industry. Exiqon operates in two business areas: Exiqon Life Sciences is a leading provider of flexible solutions for gene expression analysis. Academia, biotech and pharmaceutical companies around the world use Exiqon's research products to make ground-breaking discoveries. Exiqon Diagnostics collaborates with diagnostic and pharmaceutical companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make better treatment decisions. Exiqon is listed on Nasdaq Copenhagen. For more information about us, please visit www.exiqon.com